Compile Data Set for Download or QSAR
Report error Found 70 Enz. Inhib. hit(s) with all data for entry = 11884
TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657005(US20240076297, Example 13.4)
Affinity DataIC50: 0.300nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657010(US20240076297, Example 13.10)
Affinity DataIC50: 0.800nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656993(US20240076297, Example 5.3B | US20240076297, Examp...)
Affinity DataIC50: 0.900nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656993(US20240076297, Example 5.3B | US20240076297, Examp...)
Affinity DataIC50: 0.900nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657018(US20240076297, Example 13.18)
Affinity DataIC50: 1.10nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657003(US20240076297, Example 8.5B)
Affinity DataIC50: 1.30nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657004(US20240076297, Example 13.3)
Affinity DataIC50: 1.60nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656995(US20240076297, Example 5.4A)
Affinity DataIC50: 1.90nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656982(US20240076297, Example 4.3)
Affinity DataIC50: 2.70nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657000(US20240076297, Example 7.3A)
Affinity DataIC50: 2.80nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656987(US20240076297, Example 4.8)
Affinity DataIC50: 2.90nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656993(US20240076297, Example 5.3B | US20240076297, Examp...)
Affinity DataIC50: 3.10nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657001(US20240076297, Example 8.4B | US20240076297, Examp...)
Affinity DataIC50: 3.10nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657003(US20240076297, Example 8.5B)
Affinity DataIC50: 3.30nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656990(US20240076297, Example 4.11)
Affinity DataIC50: 3.5nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656999(US20240076297, Example 6.6)
Affinity DataIC50: 4.20nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656989(US20240076297, Example 4.10)
Affinity DataIC50: 4.40nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656986(US20240076297, Example 4.7)
Affinity DataIC50: 4.60nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656983(US20240076297, Example 4.4)
Affinity DataIC50: 4.70nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656992(US20240076297, Example 4.13)
Affinity DataIC50: 5.70nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656988(US20240076297, Example 4.9)
Affinity DataIC50: 6.10nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657022(US20240076297, Example 18.3)
Affinity DataIC50: 6.70nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656991(US20240076297, Example 4.12)
Affinity DataIC50: 7.20nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656980(US20240076297, Example 1.3)
Affinity DataIC50: 7.30nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656996(US20240076297, Example 13.17 | US20240076297, Exam...)
Affinity DataIC50: 8.20nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656985(US20240076297, Example 4.6)
Affinity DataIC50: 8.30nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656981(US20240076297, Example 4.2)
Affinity DataIC50: 8.70nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656984(US20240076297, Example 4.5)
Affinity DataIC50: 8.70nMAssay Description:Method (B): Binding affinity using SPA was conducted as follows. Test compounds (50 nL) were dispensed into individual wells of a 384-well OptiPlate&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657014(US20240076297, Example 13.14)
Affinity DataIC50: 9.10nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656995(US20240076297, Example 5.4A)
Affinity DataIC50: 9.40nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657010(US20240076297, Example 13.10)
Affinity DataIC50: 9.80nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657015(US20240076297, Example 13.15)
Affinity DataIC50: 9.80nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657001(US20240076297, Example 8.4B | US20240076297, Examp...)
Affinity DataIC50: 10.2nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657006(US20240076297, Example 13.5)
Affinity DataIC50: 10.9nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657023(US20240076297, Example 18.4)
Affinity DataIC50: 15.1nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656996(US20240076297, Example 13.17 | US20240076297, Exam...)
Affinity DataIC50: 28.1nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657011(US20240076297, Example 13.11)
Affinity DataIC50: 28.8nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657019(US20240076297, Example 16.5)
Affinity DataIC50: 43.4nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657013(US20240076297, Example 13.13)
Affinity DataIC50: 57.7nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657008(US20240076297, Example 13.8)
Affinity DataIC50: 76.9nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657006(US20240076297, Example 13.5)
Affinity DataIC50: 81.3nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657016(US20240076297, Example 13.16)
Affinity DataIC50: 107nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656998(US20240076297, Example 6.5)
Affinity DataIC50: 107nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657018(US20240076297, Example 13.18)
Affinity DataIC50: 112nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM656998(US20240076297, Example 6.5)
Affinity DataIC50: 113nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657001(US20240076297, Example 8.4B | US20240076297, Examp...)
Affinity DataIC50: 139nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657021(US20240076297, Example 17.4)
Affinity DataIC50: 145nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657012(US20240076297, Example 13.12)
Affinity DataIC50: 165nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657007(US20240076297, Example 13.7)
Affinity DataIC50: 170nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM657014(US20240076297, Example 13.14)
Affinity DataIC50: 197nMAssay Description:Method (A): 148 μL (5 μg/mL) membranes (Perkin Elmer, Cat. No. RBHA2aM400UA) and 2 μL compounds of the invention to be tested (test co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 70 total ) | Next | Last >>
Jump to: